Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly EPS (Basic) of -$1.84 for Q1 2026, down 17.27% year-over-year from -$2.22 in Q1 2025, and down 47.95% quarter-over-quarter from -$1.24 in Q4 2025.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported EPS (Basic) for 14 consecutive years, with -$1.84 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) fell 17.27% year-over-year to -$1.84; the TTM figure through Mar 2026 stood at -$5.99 (down 5.83% YoY), while the FY2025 annual figure was -$5.77, up 7.53% from the prior year.
- EPS (Basic) eased to -$1.84 in Q1 2026 per RARE's latest filing, from -$1.24 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$1.17 in Q2 2025 and bottomed at -$3.5 in Q3 2022.
- Historically, EPS (Basic) has averaged -$1.92 across 5 years, with a median of -$1.84 in 2026.
- Annual changes were most pronounced in 2022 — EPS (Basic) sank 225.33% — and 2024, when it surged 37.24%.
- Ultragenyx Pharmaceutical's EPS (Basic) stood at -$2.2 in 2022, then increased by 23.47% to -$1.68 in 2023, then gained by 15.05% to -$1.43 in 2024, then climbed by 12.9% to -$1.24 in 2025, then plunged by 47.95% to -$1.84 in 2026.
- Business Quant data shows RARE's EPS (Basic) at -$1.84 in Q1 2026, -$1.24 in Q4 2025, and -$1.81 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Ultragenyx Pharmaceutical | 1.56 Bn | 1.27 Bn | 180.00 Mn | -0.90 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.90 |
| Mar 31, 2026 | -1.84 |
| Dec 31, 2025 | -0.05 |
| Sep 30, 2025 | -1.81 |
| Jun 30, 2025 | -1.17 |
| Mar 31, 2025 | -1.57 |
| Dec 31, 2024 | -1.48 |
| Sep 30, 2024 | -1.40 |
| Jun 30, 2024 | -1.52 |
| Mar 31, 2024 | -2.03 |
| Dec 31, 2023 | -1.68 |
| Sep 30, 2023 | -2.23 |
| Jun 30, 2023 | -2.25 |
| Mar 31, 2023 | -2.33 |
| Dec 31, 2022 | -2.22 |
| Sep 30, 2022 | -3.50 |
| Jun 30, 2022 | -2.26 |
| Mar 31, 2022 | -2.19 |
| Dec 31, 2021 | -1.84 |
| Sep 30, 2021 | -1.08 |